Pedersen AN - Search Results

1

Supraclavicular recurrence after early breast cancer: a curable condition?

Pedersen AN, Møller S, Steffensen KD, Haahr V, Jensen M, Kempel MM, Jepsen SL, Madsen EL, Roslind A, Sandberg E, Schöllkopf C, Sørensen PG, Windfeldt KM, Andersson M. Pedersen AN, et al. Breast Cancer Res Treat. 2011 Feb;125(3):815-22. doi: 10.1007/s10549-010-0918-8. Epub 2010 May 8. Breast Cancer Res Treat. 2011. PMID: 20454924

2

The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.

Pedersen AN, Christensen IJ, Stephens RW, Briand P, Mouridsen HT, Danø K, Brünner N. Pedersen AN, et al. Cancer Res. 2000 Dec 15;60(24):6927-34. Cancer Res. 2000. PMID: 11156392

3

Immunoassays of urokinase (uPA) and its type-1 inhibitor (PAI-1) in detergent extracts of breast cancer tissue.

Pedersen AN, Mouridsen HT, Tenney DY, Brünner N. Pedersen AN, et al. Eur J Cancer. 2003 May;39(7):899-908. doi: 10.1016/s0959-8049(03)00025-x. Eur J Cancer. 2003. PMID: 12706358

4

Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.

Schrohl AS, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G, Foekens JA, Brunner N, Holten-Andersen MN. Schrohl AS, et al. Among authors: pedersen an. Mol Cell Proteomics. 2003 Mar;2(3):164-72. doi: 10.1074/mcp.M300019-MCP200. Epub 2003 Apr 2. Mol Cell Proteomics. 2003. PMID: 12672830 Free article.

5

The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.

Pappot H, Pedersen AN, Brünner N, Christensen IJ. Pappot H, et al. Among authors: pedersen an. Lung Cancer. 2006 Feb;51(2):193-200. doi: 10.1016/j.lungcan.2005.10.002. Epub 2005 Dec 1. Lung Cancer. 2006. PMID: 16325301

6

The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.

Pedersen AN, Høyer-Hansen G, Brünner N, Clark GM, Larsen B, Poulsen HS, Danø K, Stephens RW. Pedersen AN, et al. J Immunol Methods. 1997 Apr 11;203(1):55-65. doi: 10.1016/s0022-1759(97)00008-2. J Immunol Methods. 1997. PMID: 9134030

7

Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients.

Pedersen AN, Brünner N, Høyer-Hansen G, Hamer P, Jarosz D, Larsen B, Nielsen HJ, Stephens RW. Pedersen AN, et al. Clin Chem. 1999 Aug;45(8 Pt 1):1206-13. Clin Chem. 1999. PMID: 10430786

8

Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer.

Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Høyer-Hansen G, Brünner N, Stephens RW. Holten-Andersen MN, et al. Among authors: pedersen an. Br J Cancer. 1999 May;80(3-4):495-503. doi: 10.1038/sj.bjc.6690384. Br J Cancer. 1999. PMID: 10408859 Free PMC article.

9

Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications.

Pappot H, Gårdsvoll H, Rømer J, Pedersen AN, Grøndahl-Hansen J, Pyke C, Brünner N. Pappot H, et al. Among authors: pedersen an. Biol Chem Hoppe Seyler. 1995 May;376(5):259-67. doi: 10.1515/bchm3.1995.376.5.259. Biol Chem Hoppe Seyler. 1995. PMID: 7662168 Review.

10

ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients.

Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Høyer-Hansen G, Rønne E, Dybkjaer E, Danø K, Brünner N. Stephens RW, et al. Among authors: pedersen an. Clin Chem. 1997 Oct;43(10):1868-76. Clin Chem. 1997. PMID: 9342006

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

78 results

Search Page

Filters